Content Detail

• Content META

  Title	Reviva Pharmaceuticals (RVPH) Stock Today: Price, News, Forecast & Schizophrenia NDA Setup
  ID	29184638
  External ID	68d5f150ac2f1ad59d29807c5466aef3
  Author	Shan Ahmed Khan
  Published Date	Dec. 10, 2025, 9:56 a.m.
  Summary	Reviva Pharmaceuticals (RVPH) Stock Today: Price, News, Forecast & Schizophrenia NDA Setup – 10 December 2025 - TechStock²
  Tags
  URL	https://ts2.tech/en/reviva-pharmaceuticals-rvph-stock-today-price-news-forecast-schizophrenia-nda-setup-10-december-2025
  Sentiment	Negative: 0.24010    Neutral: 0.49266    Positive: 0.26724
  Relevance	0.03614

• Content Details

  Content ID	36775103
  Key	f707f9cf-7468-4b7f-bd6d-0c607eaf64ec
  Content	Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is back on traders' radar as a late‑stage CNS biotech preparing for a potential New Drug Application (NDA) in schizophrenia while its stock trades under $1 and analysts publish double‑ and even triple‑digit upside targets. As of mid‑session on December 10, 2025, RVPH is trading around $0.69 per share, up roughly 10% on the day, implying a market capitalization of about $78–80 million. [1] That price sits near the low end of its 12‑month range of roughly $0.25 to $3.00, with the share price still down more than 70% over the past year despite a series of positive clinical and regulatory updates. [2] Below is a structured look at all the key news, forecasts and analyses relevant to RVPH as of 10 December 2025. RVPH stock snapshot as of 10 December 2025 Latest price: about $0.69 (14:15 UTC quote: $0.6923) about (14:15 UTC quote: $0.6923) Intraday range: roughly $0.69–$0.74 today roughly today 12‑month range: about $0.25 (low) to $2.99 (high) [3] about Market cap: around $78–80 million [4] around 1‑year share performance: approximately ‑72%. [5] On December 9, MarketBeat flagged unusually high call options volume in RVPH: traders bought 27,891 call options, about 458% above average call activity, at a time when the stock was trading near $0.68. [6] That options surge is the latest sign that speculative interest is building into year‑end catalysts. Company overview: a late‑stage CNS and inflammation biotech Reviva is a late‑stage biopharmaceutical company focused on central nervous system (CNS), inflammatory and cardiometabolic diseases. [7] Its pipeline currently includes two in‑house discovered drug candidates: [8] Brilaroxazine (RP5063) – the lead asset, a serotonin–dopamine signaling modulator being developed for: Schizophrenia (core indication; late‑stage, with Phase 3 program completed) Additional neuropsychiatric indications: bipolar disorder, major depressive disorder, ADHD, Parkinson's disease psychosis, and behavioral/psychotic symptoms of dementia and Alzheimer's disease Inflammatory / respiratory indications: pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF) Psoriasis (topical/liposomal‑gel formulation planned) – the lead asset, a serotonin–dopamine signaling modulator being developed for: RP1208 – a triple reuptake inhibitor (TRI) in earlier‑stage development for depression and obesity. [9] Brilaroxazine already carries Orphan Drug Designation (ODD) from the U.S. FDA for PAH and IPF, [10] and the company has accumulated a sizable patent estate around both compounds in the U.S., Europe, China, Japan and other regions. [11] In plain language: RVPH is effectively a single‑asset, late‑stage CNS and inflammation platform, with brilaroxazine as the make‑or‑break driver of long‑term shareholder value. 2025 news timeline: what changed before December 10 1. Phase 3 RECOVER 1‑year extension data: durable efficacy & clean safety On June 2, 2025, Reviva released the full dataset from its 1‑year Phase 3 RECOVER open‑label extension (OLE) trial in stable schizophrenia patients (n=446). [12] Key findings: Broad‑spectrum, sustained efficacy over 12 months: PANSS total score: ‑18.1 points at 12 months Improvements across positive symptoms, negative symptoms, general psychopathology and social functioning 58.5% of patients had >1‑point improvement in Clinical Global Impression–Severity (CGI‑S). [13] over 12 months: Safety and tolerability: TEAEs were mostly mild or moderate; no drug‑related serious adverse events reported Minimal movement‑disorder signals , no clinically meaningful akathisia or extrapyramidal symptoms Mild, non–dose‑dependent weight gain (~1.5 kg) over one year No clinically significant cardiac, gastrointestinal or liver toxicity; improved lipid and endocrine profiles. [14] These data satisfy the 1‑year safety requirement for NDA submission in schizophrenia and reinforce the drug's differentiation versus many current antipsychotics, which are often limited by metabolic and movement‑disorder side effects. [15] Across 2025, Reviva has been showcasing the OLE dataset at major psychiatry meetings such as ASCP 2025, the CNS Summit 2025 (negative symptom data), and Neuroscience 2025 (anti‑inflammatory biomarker data). [16] 2. Q2 and Q3 2025 financials: shrinking losses but limited cash Reviva reported Q2 and Q3 2025 results with a consistent theme: no product revenue, smaller operating losses, and a modest cash cushion enhanced by equity raises. Q2 2025 (reported Aug 14, 2025): [17] Net loss: $6.05 million or $0.12 per share , down from a $7.86m loss in Q2 2024. or , down from a $7.86m loss in Q2 2024. Cash and cash equivalents: $10.4 million as of June 30, 2025 (vs. $13.5m at Dec 31, 2024). as of June 30, 2025 (vs. $13.5m at Dec 31, 2024). Operating expenses: $6.07m , primarily R&D and G&A. , primarily R&D and G&A. Completed a $10m public equity offering earlier in 2025. Q3 2025 (reported Nov 13, 2025): [18] Net loss: $4.01 million or $0.06 per share , vs. $8.37 million in Q3 2024. or , vs. in Q3 2024. Cash and cash equivalents: $13.2 million as of September 30, 2025. as of September 30, 2025. Total assets: $14.3 million ; accumulated deficit: $180.8 million . ; accumulated deficit: . Shares outstanding nearly doubled year‑over‑year (from 46.6m to 96.3m) due to equity offerings and warrant exercises. [19] The Q3 press release formalized the regulatory timeline: Pre‑NDA meeting with FDA in Q4 2025 to discuss the path to approval. to discuss the path to approval. Targeted NDA submission in Q2 2026 for schizophrenia, assuming the current data package is sufficient (a second Phase 3 RECOVER‑2 trial may or may not be required depending on FDA feedback). [20] Third‑party analysis by RTTNews on December 1, 2025 highlighted the same milestones, summarizing RVPH as 'a stock to watch' into the 2026 NDA window. [21] 3. New European patent for pulmonary fibrosis (IPF) On November 10, 2025, Reviva announced that the European Patent Office granted EP3749324, covering the use of brilaroxazine for pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF). [22] The patent complements existing protection in the U.S., China and Japan . . Brilaroxazine already holds U.S. Orphan Drug Designation for IPF and PAH. [23] This significantly strengthens Reviva's life‑cycle and multi‑indication strategy, giving the company more optionality for future partnerships or expansion beyond schizophrenia. 4. Anti‑inflammatory biomarker data at Neuroscience 2025 On November 12, 2025, Reviva announced a late‑breaking poster at the Neuroscience 2025 meeting in San Diego, presenting data on brilaroxazine's effects on BDNF and inflammatory cytokines in schizophrenia across both the acute and 1‑year OLE settings. [24] The company emphasized reduced inflammatory cytokines and improved neurotrophic markers as potential contributors to better long‑term outcomes and adherence. [25] Mechanistically, this plays into a broader story: brilaroxazine is being positioned as an antipsychotic that simultaneously modulates dopamine/serotonin and dampens neuroinflammation, a narrative that supports its use across CNS and inflammatory indications. 5. Negative symptom data at CNS Summit 2025 On October 28, 2025, Reviva announced that it would present negative symptom data for brilaroxazine from both the Phase 3 RECOVER trial and the OLE at CNS Summit 2025 in Boston. [26] Negative symptoms (apathy, lack of motivation, social withdrawal) are notoriously hard to treat and a major driver of poor functional outcomes in schizophrenia. The company is clearly pushing the angle that brilaroxazine's negative‑symptom efficacy could differentiate it in a crowded antipsychotic market. 6. Dilutive financing: $9 million public offering with dual warrants On September 18, 2025, Reviva announced, and then priced, a $9 million public offering consisting of: ~27 million shares (or equivalents) Series E and F warrants at a combined offering price of $0.335 per share. [27] This transaction improved the company's near‑term cash runway, but it also added significant future dilution via warrants on top of already rising share count, a key concern many investors have with pre‑revenue microcap biotechs. 7. Corporate events: investor conferences and AGM Lytham Partners Fall 2025 Investor Conference – Reviva participated on September 23, 2025 , keeping the story in front of small‑cap biotech investors. [28] – Reviva participated on , keeping the story in front of small‑cap biotech investors. Reviva's corporate calendar lists a board meeting on December 10, 2025 and an Annual General Meeting on December 18, 2025, both tied to the 2025 AGM agenda. [29] Simply Wall St also flags the December 18, 2025 AGM as a near‑term corporate event. [30] Financial health: runway vs. risk Reviva's 2025 financials paint a familiar biotech picture: Cash: $13.2m as of Sept 30, 2025, post multiple equity raises. [31] $13.2m as of Sept 30, 2025, post multiple equity raises. Net loss (9M 2025): $16.5m, improved from $23.7m in the prior‑year period. [32] $16.5m, improved from $23.7m in the prior‑year period. Stockholders' equity: $4.55m at Q3, up from $0.81m at year‑end 2024 due to new equity. [33] Independent platforms such as Simply Wall St describe RVPH as 'medium‑low risk with an adequate balance sheet' but simultaneously flag 'new major risk – financial position' in November 2025, explicitly pointing to balance‑sheet and funding dependence as key issues. [34] Given its burn rate and the costs of NDA preparation, potential Phase 3 RECOVER‑2, and new indication work (psoriasis, IPF, PAH), the company is widely expected to rely on additional equity or partnership funding before becoming cash‑flow positive. Analyst ratings and RVPH stock forecasts (as of December 10, 2025) Analyst and data platforms show remarkably bullish 12‑month targets relative to the current sub‑$1 share price, though they differ in methodology and sample size: TipRanks: Rating: Strong Buy based on 7 analysts in the past three months Average 12‑month price target: $5.14 Range: $2.00–$16.00 Implied upside: ~729% from the $0.62 reference price used in their model. [35] StockAnalysis.com: 6 analysts , Strong Buy Average target: $3.33 (range $2–$7 ) Implied upside: ~363% vs their latest price input. [36] MarketBeat: 9 analysts , Moderate Buy (8 Buy / 1 Sell) Average target: $3.86, range $2–$7 Implied upside: ~439% from $0.72 . [37] Benzinga (analyst‑ratings aggregation): Consensus target: $7.10 across 10 analysts , with a high of $17 and a low of $2 Most recent targets (D. Boral Capital, HC Wainwright, Chardan, Benchmark, Maxim, Roth) still sit multiple times above the current share price. [38] Investing.com: Reports an average 12‑month target of $5 , with a high of $16 and low of $2 , and a 'Strong Buy' consensus. [39] Across these sources, the common themes are: High upside vs. current price – all averages sit in the $3–$5+ range, several times the current ~$0.69 share price. Binary risk embedded in targets – the wide spread (low $2, high $16–$17) reflects very different scenarios for a successful schizophrenia launch versus regulatory or financing setbacks. Mostly positive ratings – nearly all covering analysts rate RVPH a Buy or Strong Buy, with only isolated Sell calls. [40] Forecast models also begin to factor in modest product revenue from 2026 onward (StockAnalysis cites consensus $2.9m revenue in 2026 and improving EPS from ‑$0.90 in 2024 to ‑$0.41 in 2025 and ‑$0.30 in 2026). [41] Those estimates implicitly assume brilaroxazine reaches at least early commercial stages, which is not guaranteed. Options activity, institutional ownership and retail sentiment The recent options spike on December 9 is significant: 27,891 RVPH call options traded, vs an average of ~5,000 calls, a 458% surge . traded, vs an average of ~5,000 calls, a . MarketBeat notes that the stock was trading at about $0.68, with a market cap around $78 million, and classifies the name among penny‑stock high‑volatility trades. [42] On the ownership side: MarketBeat reports that institutional ownership stands at ~63%, with funds like Persistent Asset Partners increasing positions sharply in 2025. [43] Meanwhile, retail communities (especially on Reddit penny‑stock forums) have repeatedly highlighted RVPH as a 'December catalyst' play, often tying their thesis to: The Q4 2025 pre‑NDA meeting , , The December AGM , and , and Expectations of 'violent' price moves driven by high short interest and options positioning. [44] This combination—a small float, strong institutional base, active options market, and vocal retail following—makes RVPH a stock where sentiment and news flow can produce outsized price swings in either direction. Key risks for RVPH stock Despite the upbeat clinical data and bullish analyst targets, several structural risks stand out: Single‑asset concentration Brilaroxazine is the primary value driver; RP1208 and earlier‑stage programs are not yet de‑risked. A negative outcome in FDA discussions, a demand for additional large trials, or unexpected safety findings could be devastating for the equity. [45] Funding and dilution risk Cash of $13.2m at Q3 2025 is not a large cushion for a company with multi‑indication ambitions and upcoming regulatory work. [46] at Q3 2025 is not a large cushion for a company with multi‑indication ambitions and upcoming regulatory work. Reviva has already completed multiple equity offerings in 2025 , including a $10m raise and a $9m raise with dual warrants , effectively doubling the share count in less than a year. [47] , including a and a , effectively doubling the share count in less than a year. Additional capital raises—either before or after NDA—are highly likely absent a major partnership. Regulatory uncertainty While the Phase 3 RECOVER data and 1‑year OLE results are strong, FDA feedback on the NDA package is not yet public . . The agency could request an additional Phase 3 trial (RECOVER‑2) or more long‑term data in other populations, which would add time, cost and risk. [48] Execution and commercialization risk Even if brilaroxazine is approved, Reviva will still have to launch against entrenched antipsychotic brands , potentially requiring a commercial partner or heavy sales investment. , potentially requiring a or heavy sales investment. Pricing, reimbursement, and differentiation versus existing therapies will determine whether analysts' revenue assumptions are realistic. Microcap volatility With a sub‑$100m market cap, no revenue and heavy retail interest, RVPH is structurally prone to extreme volatility around every piece of news—from FDA scheduling updates to small changes in analyst targets. [49] Investment takeaway: how to think about RVPH as of December 10, 2025 From a fundamentals‑plus‑catalyst perspective, Reviva Pharmaceuticals sits at a classic late‑stage biotech crossroads: Bull case highlights Convincing Phase 3 and 1‑year OLE data in schizophrenia, with meaningful improvements in negative symptoms and a favorable safety/metabolic profile. [50] Strengthening IP around pulmonary fibrosis and PAH , opening up multiple potential indications beyond schizophrenia. [51] A clear regulatory roadmap : pre‑NDA meeting in Q4 2025 and targeted NDA submission in Q2 2026 , making the next 12–18 months rich in catalysts. [52] Broadly bullish analyst coverage , with consensus targets multiple times above today's price. [53] Bear case highlights A single, unapproved lead asset and an accumulated deficit of about $181m . [54] Limited cash runway and a demonstrated reliance on dilutive financing, including offerings with attached warrants. [55] The possibility that FDA feedback could materially delay or complicate the NDA plan, forcing additional trials and capital raises. [56] High volatility amplified by options speculation and retail trading. [57] For risk‑tolerant investors, RVPH is essentially a leveraged bet on brilaroxazine's NDA path and eventual commercial adoption in schizophrenia and—longer term—fibrotic and inflammatory indications. For more conservative investors, the combination of financing risk, regulatory uncertainty, and microcap volatility may outweigh the attractive analyst price targets. Either way, as of December 10, 2025, RVPH is firmly a catalyst‑driven biotech story, with the pre‑NDA meeting outcome, AGM messaging, and 2026 NDA timeline likely to shape the next major moves in the stock. References 1. simplywall.st, 2. www.marketbeat.com, 3. www.marketbeat.com, 4. www.marketbeat.com, 5. simplywall.st, 6. www.marketbeat.com, 7. www.reuters.com, 8. revivapharma.com, 9. www.reuters.com, 10. revivapharma.com, 11. revivapharma.com, 12. revivapharma.com, 13. revivapharma.com, 14. revivapharma.com, 15. revivapharma.com, 16. revivapharma.com, 17. revivapharma.com, 18. revivapharma.com, 19. revivapharma.com, 20. revivapharma.com, 21. www.rttnews.com, 22. revivapharma.com, 23. revivapharma.com, 24. revivapharma.com, 25. revivapharma.com, 26. revivapharma.com, 27. www.globenewswire.com, 28. finance.yahoo.com, 29. us.trendlyne.com, 30. simplywall.st, 31. revivapharma.com, 32. revivapharma.com, 33. revivapharma.com, 34. simplywall.st, 35. www.tipranks.com, 36. stockanalysis.com, 37. www.marketbeat.com, 38. www.benzinga.com, 39. www.investing.com, 40. www.marketbeat.com, 41. stockanalysis.com, 42. www.marketbeat.com, 43. www.marketbeat.com, 44. www.reddit.com, 45. www.reuters.com, 46. revivapharma.com, 47. revivapharma.com, 48. revivapharma.com, 49. www.marketbeat.com, 50. revivapharma.com, 51. revivapharma.com, 52. revivapharma.com, 53. www.tipranks.com, 54. revivapharma.com, 55. revivapharma.com, 56. www.rttnews.com, 57. www.marketbeat.com
  Content Reference URL	None

• Publisher

  Publisher Name	ts2.tech (#20595)
  Publisher URL	https://ts2.tech/
  Description	None
  Trust Flow Score	25
  Citation Flow Score	54

• Data Source

  Data Source Name	NewsCatcher (#303)
  Data Source Type	news
  Data Source URL	https://www.newscatcherapi.com/
  Description
  Weight	1